{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T12:31:29Z","timestamp":1748435489081},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Peking University People's Hospital Scientific Research Development Funds","award":["RDJ2022-21"],"award-info":[{"award-number":["RDJ2022-21"]}]},{"name":"Peking University Hepatology Institute Qi-Min Project","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Bristol-Myers Squibb","award":["AI452-018ST"],"award-info":[{"award-number":["AI452-018ST"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To investigate the trends in health-related quality of life (HRQoL) among hepatitis C virus (HCV) patients and to assess the longitudinal impact of antiviral therapy on their well-being.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this prospective multicenter observational study in adults with HCV infection, sociodemographic, clinical characteristics and EQ-5D questionnaires were collected. Generalized estimating equation (GEE) models were used to assess the associations between these variables and changes in HRQoL over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>456 patients were included, with a median age of 46.5 (36.5\u201357.0) years, of which 262 (57.5%) were males and 44 (9.6%) had cirrhosis. 335 patients (73.5%) receiving antiviral therapy and 61.8% achieved sustained virologic response (SVR). The baseline EQ-5D utility and EQ-VAS were 0.916\u2009\u00b1\u20090.208 and 80.6\u2009\u00b1\u200913.0. In multivariable analysis of GEE estimation, achieving SVR24 was positively associated with EQ-5D utility (<jats:italic>p<\/jats:italic>\u2009=\u20090.000) and EQ-VAS (<jats:italic>p<\/jats:italic>\u2009=\u20090.000) over time. Age and income were shown to be significant predictors of EQ-5D utility, while gender, age and genotype were associated with EQ-VAS over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>SVR improved long-term HRQoL in HCV patients in the first few years following viral clearance. Certain sociodemographic factors, such as gender, age, income as well as genotype, significantly influenced long-term changes in patients\u2019 quality of life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT01594554. Registration date: 09\/05\/2012.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08940-3","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T17:02:27Z","timestamp":1704906147000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sustained virologic response improved the long-term health-related quality of life in patients with chronic hepatitis C: a prospective national study in China"],"prefix":"10.1186","volume":"24","author":[{"given":"Rui","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiying","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"8940_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","volume":"8","author":"F Cui","year":"2023","unstructured":"Cui F, Blach S, Manzengo Mingiedi C, Gonzalez MA, Sabry Alaama A, Mozalevskis A, et al. Global reporting of progress towards elimination of Hepatitis B and Hepatitis C. Lancet Gastroenterol Hepatol. 2023;8:332\u201342.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"8940_CR2","unstructured":"WHO, Global hepatitis report. 2017. https:\/\/apps.who.int\/iris\/bit, 2020."},{"key":"8940_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/hep.31060","volume":"71","author":"MG Ghany","year":"2020","unstructured":"Ghany MG, Morgan TR. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and treating Hepatitis C virus Infection. Hepatology. 2020;71:686\u2013721.","journal-title":"Hepatology"},{"key":"8940_CR4","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"EASL recommendations on treatment of hepatitis C","year":"2020","unstructured":"EASL recommendations on treatment of hepatitis C. Final update of the series(\u2606). J Hepatol. 2020;73:1170\u2013218.","journal-title":"J Hepatol"},{"key":"8940_CR5","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.3748\/wjg.v28.i41.5910","volume":"28","author":"YB Liu","year":"2022","unstructured":"Liu YB, Chen MK. Epidemiology of liver Cirrhosis and associated Complications: current knowledge and future directions. World J Gastroenterol. 2022;28:5910\u201330.","journal-title":"World J Gastroenterol"},{"key":"8940_CR6","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1111\/liv.15347","volume":"42","author":"N Veracruz","year":"2022","unstructured":"Veracruz N, Gish RG, Cheung R, Chitnis AS, Wong RJ. Global trends and the impact of chronic Hepatitis B and C on disability-adjusted life years. Liver Int. 2022;42:2145\u201353.","journal-title":"Liver Int"},{"key":"8940_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/jvh.13741","volume":"29","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Yu ML, El-Kassas M, Esmat G, Castellanos Fern\u00e1ndez MI, Buti M, et al. Severe impairment of patient-reported outcomes in patients with chronic Hepatitis C virus Infection seen in real-world practices across the world: data from the global liver registry. J Viral Hepat. 2022;29:1015\u201325.","journal-title":"J Viral Hepat"},{"key":"8940_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12955-018-0941-8","volume":"16","author":"R Huang","year":"2018","unstructured":"Huang R, Rao H, Shang J, Chen H, Li J, Xie Q, et al. A cross-sectional assessment of health-related quality of life in Chinese patients with chronic Hepatitis C virus Infection with EQ-5D. Health Qual Life Outcomes. 2018;16:124.","journal-title":"Health Qual Life Outcomes"},{"key":"8940_CR9","doi-asserted-by":"crossref","unstructured":"Wong WWL, Wong J, Bremner KE, Saeed Y, Mason K, Phoon A et al. Impact of direct-acting antiviral treatment on health utility in patients with chronic Hepatitis C in hospital and community settings. Liver Int. 2023.","DOI":"10.1111\/liv.15518"},{"key":"8940_CR10","doi-asserted-by":"publisher","first-page":"100705","DOI":"10.1016\/j.aohep.2022.100705","volume":"27","author":"N He","year":"2022","unstructured":"He N, Feng G, Hao S, Xu M, Liu J, Kong F, et al. The impact of direct-acting antivirals on quality of life in patients with Hepatitis C virus Infection: a meta-analysis. Ann Hepatol. 2022;27:100705.","journal-title":"Ann Hepatol"},{"key":"8940_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/jvh.13234","volume":"27","author":"JC Sung","year":"2020","unstructured":"Sung JC, Bosh C, Wyatt B, Miller M, Harty A, Del Bello D, et al. Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center. J Viral Hepat. 2020;27:350\u201359.","journal-title":"J Viral Hepat"},{"key":"8940_CR12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/liv.14781","volume":"41","author":"M Serper","year":"2021","unstructured":"Serper M, Evon DM, Amador J, Stewart PW, Sarkar S, Lok AS, et al. Patient-reported outcomes 12 months after Hepatitis C treatment with direct-acting antivirals: results from the PROP UP study. Liver Int. 2021;41:692\u2013704.","journal-title":"Liver Int"},{"key":"8940_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/jgh.13467","volume":"32","author":"HY Rao","year":"2017","unstructured":"Rao HY, Li H, Chen H, Shang J, Xie Q, Gao ZL, et al. Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study. J Gastroenterol Hepatol. 2017;32:244\u201352.","journal-title":"J Gastroenterol Hepatol"},{"key":"8940_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3851\/IMP3334","volume":"24","author":"H Rao","year":"2019","unstructured":"Rao H, Xie Q, Shang J, Gao Z, Chen H, Sun Y, et al. Real-world clinical outcomes among individuals with chronic HCV Infection in China: CCgenos study. Antivir Ther. 2019;24:473\u201383.","journal-title":"Antivir Ther"},{"key":"8940_CR15","doi-asserted-by":"crossref","unstructured":"Songtanin B, Nugent K. Burden, Outcome, and comorbidities of Extrahepatic manifestations in Hepatitis C virus Infection. Biology (Basel). 2022; 12.","DOI":"10.3390\/biology12010023"},{"key":"8940_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.7326\/M19-3860","volume":"174","author":"GM Abraham","year":"2021","unstructured":"Abraham GM, Obley AJ, Humphrey LL, Qaseem A, Centor RM, Akl E, et al. World Health Organization Guidelines on treatment of Hepatitis C virus Infection: best practice advice from the American College of Physicians. Ann Intern Med. 2021;174:98\u2013100.","journal-title":"Ann Intern Med"},{"key":"8940_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jval.2014.05.007","volume":"17","author":"GG Liu","year":"2014","unstructured":"Liu GG, Wu H, Li M, Gao C, Luo N. Chinese time trade-off values for EQ-5D health states. Value Health. 2014;17:597\u2013604.","journal-title":"Value Health"},{"key":"8940_CR18","unstructured":"Cheng Q, Cunningham EB, Shih S, Amin J, Bruneau J, Artenie AA et al. Patient-reported outcomes during and after Hepatitis C Virus Direct-acting antiviral treatment among people who inject Drugs. Value Health. 2023."},{"key":"8940_CR19","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.aohep.2019.04.015","volume":"18","author":"V de Ledinghen","year":"2019","unstructured":"de Ledinghen V, Hanslik B, Moussalli J, Si Ahmed SN, Ouzan D, Larrey D. Hepatitis C virus Infection impacts work productivity and fatigue: an epidemiologic real-life study. Ann Hepatol. 2019;18:708\u201314.","journal-title":"Ann Hepatol"},{"key":"8940_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jval.2019.07.005","volume":"23","author":"YA Saeed","year":"2020","unstructured":"Saeed YA, Phoon A, Bielecki JM, Mitsakakis N, Bremner KE, Abrahamyan L, et al. A systematic review and Meta-analysis of Health utilities in patients with chronic Hepatitis C. Value Health. 2020;23:127\u201337.","journal-title":"Value Health"},{"key":"8940_CR21","doi-asserted-by":"publisher","first-page":"e0215596","DOI":"10.1371\/journal.pone.0215596","volume":"14","author":"S Cossais","year":"2019","unstructured":"Cossais S, Schwarzinger M, Pol S, Fontaine H, Larrey D, Pageaux GP, et al. Quality of life in patients with chronic Hepatitis C Infection: severe comorbidities and Disease perception matter more than Liver-Disease stage. PLoS ONE. 2019;14:e0215596.","journal-title":"PLoS ONE"},{"key":"8940_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3138\/canlivj-2022-0009","volume":"6","author":"YA Saeed","year":"2023","unstructured":"Saeed YA, Mason K, Mitsakakis N, Feld JJ, Bremner KE, Phoon A, et al. Disparities in health utilities among Hepatitis C patients receiving care in different settings. Can Liver J. 2023;6:24\u201338.","journal-title":"Can Liver J"},{"key":"8940_CR23","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/jvh.13546","volume":"28","author":"V Ohlendorf","year":"2021","unstructured":"Ohlendorf V, Sch\u00e4fer A, Christensen S, Heyne R, Naumann U, Link R, et al. Only partial improvement in health-related quality of life after treatment of chronic Hepatitis C virus Infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). J Viral Hepat. 2021;28:1206\u201318.","journal-title":"J Viral Hepat"},{"key":"8940_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/MEG.0000000000000860","volume":"29","author":"CS North","year":"2017","unstructured":"North CS, Pollio DE, Sims OT, Jain MK, Brown GR, Downs DL, et al. An effectiveness study of group psychoeducation for Hepatitis C patients in community clinics. Eur J Gastroenterol Hepatol. 2017;29:679\u201385.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"8940_CR25","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/liv.14403","volume":"40","author":"M O\u2019Sullivan","year":"2020","unstructured":"O\u2019Sullivan M, Jones AM, Gage H, Jordan J, MacPepple E, Williams H, et al. ITTREAT (Integrated Community Test - Stage - TREAT) Hepatitis C service for people who use Drugs: real-world outcomes. Liver Int. 2020;40:1021\u201331.","journal-title":"Liver Int"},{"key":"8940_CR26","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/jvh.13516","volume":"28","author":"S Goutzamanis","year":"2021","unstructured":"Goutzamanis S, Spelman T, Harney B, Dietze P, Stoove M, Higgs P, et al. Patient-reported outcomes of the treatment and Prevention Study: a real-world community-based trial of direct-acting antivirals for Hepatitis C among people who inject Drugs. J Viral Hepat. 2021;28:1068\u201377.","journal-title":"J Viral Hepat"},{"key":"8940_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jhep.2015.03.014","volume":"63","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Stepanova M, Afdhal N, Kowdley KV, Zeuzem S, Henry L, et al. Improvement of health-related quality of life and work productivity in chronic Hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63:337\u201345.","journal-title":"J Hepatol"},{"key":"8940_CR28","doi-asserted-by":"publisher","first-page":"822","DOI":"10.12669\/pjms.38.4.4537","volume":"38","author":"B Ali","year":"2022","unstructured":"Ali B, Raja IUH, Choudhry A, Nawaz AA. Successful eradication of Hepatitis-C virus with Sofosbuvir based antiviral treatment results in improvement in quality of life in cirrhotic patients. Pak J Med Sci. 2022;38:822\u201325.","journal-title":"Pak J Med Sci"},{"key":"8940_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/jgh3.12462","volume":"5","author":"SM McPhail","year":"2021","unstructured":"McPhail SM, Amarasena S, Stuart KA, Hayward K, Gupta R, Brain D, et al. Assessment of health-related quality of life and health utilities in Australian patients with Cirrhosis. JGH Open. 2021;5:133\u201342.","journal-title":"JGH Open"},{"key":"8940_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S2468-1253(16)30009-7","volume":"1","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Charlton M, Curry MP, O\u2019Leary JG, Brown RS, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without Ribavirin for Hepatitis C virus-related decompensated Cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016;1:122\u201332.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"8940_CR31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2019.04.016","volume":"71","author":"DM Evon","year":"2019","unstructured":"Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, et al. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic Hepatitis C: the PROP UP study. J Hepatol. 2019;71:486\u201397.","journal-title":"J Hepatol"},{"key":"8940_CR32","doi-asserted-by":"publisher","first-page":"100665","DOI":"10.1016\/j.jhepr.2022.100665","volume":"5","author":"F Marcellin","year":"2023","unstructured":"Marcellin F, Mourad A, Lemoine M, Kouanfack C, Seydi M, Carrieri P, et al. Patient-reported outcomes with direct-acting antiviral treatment for Hepatitis C in West and Central Africa (TAC ANRS 12311 trial). JHEP Rep. 2023;5:100665.","journal-title":"JHEP Rep"},{"key":"8940_CR33","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1007\/s11136-021-02874-6","volume":"30","author":"A Miyasaka","year":"2021","unstructured":"Miyasaka A, Yoshida Y, Suzuki A, Takikawa Y. Health-related quality of life in patients with chronic Hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response. Qual Life Res. 2021;30:3501\u201309.","journal-title":"Qual Life Res"},{"key":"8940_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.17235\/reed.2019.6063\/2018","volume":"111","author":"S Go\u00f1i Esarte","year":"2019","unstructured":"Go\u00f1i Esarte S, Juanbeltz R, Mart\u00ednez-Baz I, Castilla J, San Miguel R, Herrero JI, et al. Long-term changes on health-related quality of life in patients with chronic Hepatitis C after viral clearance with direct-acting antiviral agents. Rev Esp Enferm Dig. 2019;111:445\u201352.","journal-title":"Rev Esp Enferm Dig"},{"key":"8940_CR35","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.2169\/internalmedicine.5102-20","volume":"59","author":"T Ichikawa","year":"2020","unstructured":"Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, et al. Direct-acting antivirals improved the quality of life, ameliorated Disease-related symptoms, and augmented muscle volume three years later in patients with Hepatitis C Virus. Intern Med. 2020;59:2653\u201360.","journal-title":"Intern Med"},{"key":"8940_CR36","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.cgh.2021.01.026","volume":"20","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Racila A, Muir A, Bourliere M, Mangia A, Esteban R, et al. Long-term patient-centered outcomes in cirrhotic patients with chronic Hepatitis C after achieving sustained Virologic Response. Clin Gastroenterol Hepatol. 2022;20:438\u201346.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8940_CR37","doi-asserted-by":"crossref","unstructured":"Slonka J, Piotrowski D, Janczewska E, Pisula A, Musialik J, Jaroszewicz J. Significant decrease in the prevalence of anxiety and depression after Hepatitis C eradication. J Clin Med. 2022; 11.","DOI":"10.3390\/jcm11113044"},{"key":"8940_CR38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jvh.13668","volume":"29","author":"H Kaur","year":"2022","unstructured":"Kaur H, Dhiman RK, Kulkarni AV, Premkumar M, Singh V, Duseja AK, et al. Improvement of chronic HCV infection-related depression, anxiety, and neurocognitive performance in persons achieving SVR-12: a real-world cohort study. J Viral Hepat. 2022;29:395\u2013406.","journal-title":"J Viral Hepat"},{"key":"8940_CR39","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez-Rojas L, de la G\u00e1ndara Mart\u00edn JJ, Garc\u00eda Buey L, Uriz Otano JI, Mena \u00c1, Roncero C. Patients with severe mental Illness and Hepatitis C virus Infection benefit from new pangenotypic direct-acting antivirals: results of a literature review. Gastroenterol Hepatol. 2022.","DOI":"10.1016\/j.gastrohep.2022.06.001"},{"key":"8940_CR40","doi-asserted-by":"crossref","unstructured":"Kr\u00fcger K, Rossol S, Krauth C, Buggisch P, Mauss S, Stoehr A et al. Real-world experience for the outcomes and costs of treating Hepatitis C patients: results from the German Hepatitis C-Registry (DHC-R). Z Gastroenterol. 2022.","DOI":"10.1055\/a-1852-5713"},{"key":"8940_CR41","first-page":"9450","volume":"8","author":"G Bertino","year":"2020","unstructured":"Bertino G, Ragusa R, Corsaro LS, Frazzetto E, Messina V, Inguscio L, et al. Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2). Health Psychol Res. 2020;8:9450.","journal-title":"Health Psychol Res"},{"key":"8940_CR42","doi-asserted-by":"publisher","first-page":"e0237005","DOI":"10.1371\/journal.pone.0237005","volume":"15","author":"RN Fagundes","year":"2020","unstructured":"Fagundes RN, Ferreira L, Pace FHL. Health-related quality of life and fatigue in patients with chronic Hepatitis C with therapy with direct-acting antivirals agents interferon-free. PLoS ONE. 2020;15:e0237005.","journal-title":"PLoS ONE"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08940-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08940-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08940-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T17:02:43Z","timestamp":1704906163000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08940-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8940"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08940-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"14 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocols were approved by a central review board (the ethics committee of Peking University People\u2019 s Hospital), the institutional review boards of each participating center, and the China National Human Genetic Resource Management Office (2010). All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all subjects and\/or their legal guardian(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LW has received research grants from Abbvie, Bristol-Myers Squibb, and Gilead, and consulting for Gilead, Huahui, MSD, Pfizer, speaker for Ascletis Pharma, Bristol- Myers Squibb, Gilead, and Kaiyin. HR has received a speaker honorarium from Bristol-MyersSquibb, Gilead, and AbbVie. Other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}